It was another volatile week for new stocks. The IPO Index returned -0.5%, underperforming the S&P 500’s +1.2%. Software led ...

While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two more on the calendar for the week ahead.RNA interference biotech City ...

Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company.Autoimmune biotech ...

Patriot Mobile, a wireless communications company focused on Christian-conservative organizations, filed on Friday with the ...

Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, filed on Friday with the SEC ...

OPay, a digital bank and fintech platform in Nigeria and other emerging markets, filed on Friday with the SEC for an initial public offering we estimate could raise up to $500 million.

Vardis Holding, which sells proprietary non-invasive restorative treatments for early-stage cavities, filed on Friday with the SEC for an initial public offering that we estimate could raise $200 ...

Simwon America, an electric vehicle structural components manufacturer being spun out of Korea's MS Autotech, filed on Friday with the SEC to raise up to $50 million in an initial public offering. The ...

City Therapeutics, a Phase 1 biotech developing RNA interference therapies for thromboembolic diseases, announced terms for ...

TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, raised $117 million by offering 8.3 million shares at $14, the low end of the $14 to $16 range. Eli Lilly, an ...

Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, raised $45 million by ...